Recomendaciones de la Sociedad Española de Diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2: Actualización 2018
Gomez-Peralta, F. (Autor de correspondencia); Escalada San Martín, Francisco Javier
; Torre, E. M.; Cases, M. M.; Garcia, J. C. F. ; Loiola, P. E.; Lachica, L. A.; Perez, J. A. F.; Menendez, S. A. ; Alvarez-Guisasola, F. ; Echevarrian, I. R.; Borras, J. G.
Type 2 diabetes mellitus (DM2) has become a problem of global dimensions by their high and growing prevalence worldwide and the personal and economic costs associated with it. Correct treatment can reduce mortality and associated complications. New concepts have recently been included in routine clinical practice and have changed the algorithm of DM2 pharmacological therapy. Therefore, the Spanish Society of Diabetes (SED) entrusted to the Working Group of Consensus and Clinical Guidelines an update of the 2010 document Recommendations for Pharmacological Treatment of Hyperglycemia in Diabetes type 2. Novel aspects include nine characteristics to describe each drug group: efficiency, the risk of hypoglycemia, effects on body weight, the demonstrated effect in cardiovascular risk, nephroprotection, limitation of use in renal insufficiency, the rate of secondary effects, complexity and costs. Additionally, the document details combination options, and develop the start and adjustment of available injectable therapies. (C) 2018 SEEN y SED. Published by Elsevier Espana, S.L.U. All rights reserved.